BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) announced Monday that it has applied for patent protection for its new 2-Bromo-LSD (TD-0148A) formulations to treat depression and mood disorders.
2-Bromo-LSD is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the psychedelic effects or hallucinations.
BetterLife noted that its recent C$10 million acquisition of the assets of Transcend Biodynamics makes it the only company able to synthesize 2-Bromo-LSD utilizing a patented process which obviates the need to first synthesize LSD-25 — eliminating the regulatory barriers of working with a Schedule 1 substance.
“The invention covered by this provisional patent filing holds great promise for the treatment of various psychiatric disorders, and helps us advance on our path to becoming a leader in the psychedelic drug space which is estimated to become a $6.85 billion dollar industry by 2027 alone,” said BetterLife CEO Ahmad Doroudian in a statement.
“We are excited to be developing and bringing to market treatments addressing a range of mental health conditions, including depression and anxiety.”
BetterLife, based in Vancouver, also is developing drug candidates from a broad set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus (COVID-19) and human papillomavirus, or to directly inhibit tumors to treat specific types of cancer.
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham